The strangest fact in this month's nuclear rally is who missed it. BWX Technologies, the Lynchburg, Virginia manufacturer that builds reactors for U.S. Navy submarines and components for commercial plants, delivered the best quarter of any profitable company in the group — revenue up 18% year over year to $902m, full-year guidance raised across revenue, earnings and free cash flow, and a backlog of $8.4bn that has grown 40% in a year with orders coming in at 1.7x the rate of billings. The stock fell about 2% over the past 30 days and has gone nowhere in twelve months. Meanwhile uranium miners and pre-revenue reactor startups with far weaker quarters rallied double digits.

Three days did the work

The group's advance looks broad by name: seven of nine stocks rose, led by Centrus Energy up 21.5% and Energy Fuels up 19.2%, with the AI-narrative favorite Oklo actually down 2.9%. But it is narrow by time. Remove each stock's two best sessions and every single member's 30-day return drops to roughly zero or below.

Those best sessions cluster on three dates. On July 30, six of the nine had their single best day after the Nuclear Regulatory Commission (NRC) accepted Holtec International's plan to build four small modular reactors (SMRs) totaling 1.36 gigawatts at the retired Oyster Creek site in New Jersey — a project belonging to none of these companies. The rest came on July 21 and during the August 5–7 earnings week. This is a sector repricing on shared headlines, not investors accumulating individual businesses.

The fuel cycle: real prices, rich multiples

The underlying commodity story checks out. Long-term uranium contract prices reached an 18-year high near $94/lb while spot sits around $86.5/lb — term leading spot is the signature of utilities locking in supply against a structural deficit.

Cameco, the Canadian uranium producer and fuel-services company supplying utilities worldwide, said on its July 31 call that long-term prices are tracking toward $100-plus and that its contracted deliveries average more than 28m lb a year. Its headline quarter looked ugly — net income down 92% — but the comparison is distorted by a one-off Westinghouse payment in the prior year, and production guidance was unchanged. The trouble is the price of admission: 166x trailing earnings and 60x forward, against consensus revenue growth of just 2.8% this year. Buyers are paying now for an earnings ramp consensus puts at $2.64 per share in 2027 rising to $4.10 in 2029.

Centrus Energy, the only U.S.-owned commercial uranium enricher and sole licensed domestic producer of the high-assay fuel (HALEU) advanced reactors need, is the same trade in sharper form. Its backlog surged to $4.5bn stretching to 2040, with definitive HALEU offtakes from X-energy and a letter of intent from Oklo, both carrying prepayments. But the current business is going the other way: second-quarter operating income fell 69%, enrichment volumes dropped 23%, and consensus has this year's earnings down 43%. At 74x forward earnings, the stock's 21.5% month was bought on the 2030s, not the income statement.

Energy Fuels, a U.S. uranium and rare-earth miner, grew revenue nearly sixfold to $25.1m but still lost $33.4m; its 15% post-earnings jump rode a $725m government loan supporting its mine-to-magnet buildout. Uranium Energy Corp, which holds uranium inventory and projects it sells opportunistically, reported zero revenue last quarter, a $52.3m loss, and a share count up 23% in six quarters.

The developers: milestones funded by the printer

The four reactor startups are where the twelve-month damage lives — NuScale Power down 74%, Lightbridge down 48%, Nano Nuclear down 44%, Oklo down 40% — and the numbers say that de-rating was earned. Oklo, the Sam Altman-backed fast-reactor developer, has genuine milestones, including Department of Energy design approval for its Idaho plant, but raised $1.9bn through at-the-market share sales this year and lifted its own spending guidance to as much as $150m of operating cash use plus $500m of plant investment. NuScale, the only SMR firm with NRC design certification, booked $75,000 of revenue last quarter — down from $8.1m — while its long-awaited Tennessee Valley Authority power agreement remains unsigned. Lightbridge, a nuclear-fuel technology developer, and Nano Nuclear, a microreactor startup, are both effectively pre-revenue and both funded by fresh issuance.

The demand story these names trade on is real but distant: hyperscalers have committed roughly 9.8 GW of nuclear capacity across 13 deals, yet only about 1.9 GW is operational, and Carnegie Endowment analysis warns announced timelines exceed what U.S. deployment can deliver.

The odd one out

Which brings it back to BWXT. Its one genuine soft spot is margin: operating margin compressed to about 10% in the first half from 14% a year earlier as it invests in capacity, with recovery guided to 2027. That is a real cost, but it sits beside 20% expected revenue growth and a multiple — 36.5x forward earnings — that is the most reasonable growth-adjusted valuation among the group's profitable members. The market spent a month paying up for uranium optionality and SMR headlines while marking down the one company whose backlog is already contracted.

The setup

Where it stands — The group's 17% month rests on three news dates; BWXT, with the strongest reported quarter, sat it out entirely. Would confirm — BWXT operating margin turns back toward 14% while backlog holds above $8bn, closing the gap between results and the share price. Would invalidate — Long-term uranium prices roll below $90/lb or BWXT's book-to-bill drops under 1x, removing the contracted-demand floor. Watch next — NuScale's Tennessee Valley Authority power-agreement signing and the group's third-quarter reports in early November. Valuation — BWXT at 44.6x trailing / 36.5x forward earnings on 20% growth, versus Cameco at 166x/60x on 2.8% growth.